The recently concluded Pulmonary Fibrosis Foundation (PFF)’s third biennial scientific conference, Summit 2015: From Bench to Bedside, achieved a record attendance of over 700 people — from pulmonary fibrosis researchers, academics and healthcare specialists to industry front-runners and PF patients/caregivers — representing 18 countries. Attendees presented research and discussed new treatments in a collaborative setting…
PFF’s Summit 2015 Sets Records for Attendance, Scientific Studies
Veracyte, Inc.recently presented four abstracts on current diagnostic challenges related to interstitial lung disease (ILD) and the potential for improved diagnostic procedures using novel genomic-based strategies. The abstracts were given at the Pulmonary Fibrosis Foundation’s PFF Summit 2015: From Bench to Bedside at the JW Marriott Hotel…
A team of researchers report that a mouse’s age influences the ability of its mesenchymal stem cells to repair pulmonary fibrosis-induced damage, a finding with significant implications for stem cell therapies. The study, “Therapeutic benefits of young, but not old, adipose-derived mesenchymal stem cells in a chronic mouse model of bleomycin-induced pulmonary fibrosis,”…
Colin was diagnosed with idiopathic pulmonary fibrosis. Watch the video to see his testimony. Learn more about IPF : https://bit.ly/1QiRmr3…
Afferent Pharmaceuticals, a biotechnology company dedicated to therapies for neurogenic disorders, recently announced the beginning of a Phase 2 clinical trial to assess its candidate product AF-219 for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF). Neurogenic disorders are conditions associated with the central nervous…
Read the articles here: 1. Potential Therapy for Severe Lung Disease Advances at aTyr Pharma 2. New Anti-Fibrotic Drug Candidate MRG-201 Enters Phase 1 Clinical Trial 3. Genentech’s IPF Therapy Found to Improve Lung Function over Time…
The nonprofit phaware global association (phaware), an organization focused on raising awareness of pulmonary hypertension, has developed a new mobile app (phaware365) to help achieve its goal globally through an innovative and engaging strategy. Pulmonary hypertension (PH) is a life-threatening cardiopulmonary disorder characterized by an abnormally high blood pressure…
New data from Phase 3 clinical studies of Genentech’s Esbriet (pirfenidone), a drug developed for the treatment of pulmonary fibrosis (PF), showed the treatment’s efficacy over time. The data presentation, the “Effect of continued treatment with pirfenidone following a clinically meaningful decline in percent predicted forced vital capacity in…
Watch the video to learn a little bit more about Pulmonary Fibrosis, causes, symptoms and signs. Learn more about PF here: https://bit.ly/1lfMsiZ…
The Pulmonary Fibrosis Foundation (PFF), an organization whose goal is to raise awareness, offer disease education, advance care, and fund research in the field of pulmonary fibrosis (PF), announced in a press release that Genentech, a biotechnology company part of the Roche Group, will assume the role…
